BTAI Stock Price, Bioxcel Therapeutics Inc Quote, Chart

Market Summary

USD2.12-0.06

Market Closed

-2.75%

BTAI Stock Price

View Fullscreen

BTAI RSI Chart

BTAI Valuation

Market Cap

79.6M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

45.31

Price/Free Cashflow

-0.66

BTAI Price/Sales (Trailing)

BTAI Profitability

Return on Equity

211.5%

Return on Assets

-185.91%

Free Cashflow Yield

-151.3%

BTAI Fundamentals

BTAI Revenue

Revenue (TTM)

1.8M

Rev. Growth (Yr)

182.52%

Rev. Growth (Qtr)

54.79%

BTAI Earnings

Earnings (TTM)

-153.0M

Earnings Growth (Yr)

49.26%

Earnings Growth (Qtr)

-20.38%

Breaking Down BTAI Revenue

Last 7 days

-13.1%

Last 30 days

-24.8%

Last 90 days

-11.4%

Trailing 12 Months

-92.1%

How does BTAI drawdown profile look like?

BTAI Financial Health

Current Ratio

2.57

Debt/Equity

-1.4

Debt/Cashflow

-1.18

BTAI Investor Care

Shares Dilution (1Y)

28.71%

Diluted EPS (TTM)

-5.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.8M	0	0	0
2023	626.3K	877.5K	1.1M	1.4M
2022	0	0	0	375.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Bioxcel Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	steinhart richard i	sold	-2,816	2.635	-1,069	chief financial officer
Apr 04, 2024	wiley matthew t.	sold	-2,656	2.6351	-1,008	chief commercial officer
Apr 04, 2024	rodriguez javier	sold	-2,667	2.6358	-1,012	see remarks
Apr 04, 2024	mehta vimal	sold	-13,823	2.62396	-5,268	ceo and president
Apr 04, 2024	o'neill vincent	sold	-432	2.6211	-165	see remarks
Apr 04, 2024	yocca frank	sold	-2,811	2.635	-1,067	chief scientific officer
Mar 15, 2024	steinhart richard i	acquired	-	-	2,250	chief financial officer
Mar 15, 2024	o'neill vincent	acquired	-	-	2,250	see remarks
Mar 15, 2024	rodriguez javier	acquired	-	-	2,250	see remarks
Mar 15, 2024	mehta vimal	acquired	-	-	14,000	ceo and president

Which funds bought or sold BTAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	FMR LLC	reduced	-0.97	-396,357	7,033,410	-%
May 13, 2024	UBS Group AG	added	204	272,439	414,983	-%
May 13, 2024	Creative Planning	reduced	-34.61	-22,369	37,292	-%
May 13, 2024	Crossmark Global Holdings, Inc.	sold off	-100	-38,000	-	-%
May 13, 2024	Nuveen Asset Management, LLC	sold off	-100	-43,684	-	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	1.71	-36,829	1,291,480	-%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	-176	3,807	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	2.3	-657	29,088	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	new	-	67,000	67,000	-%
May 13, 2024	XTX Topco Ltd	new	-	88,018	88,018	0.01%

Are Funds Buying or Selling BTAI?

Are funds buying BTAI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BTAI

No. of Funds

Unveiling Bioxcel Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	1.55%	465,381	SC 13G/A
Oct 19, 2023	bioxcel holdings, inc.	30.1%	8,901,750	SC 13G/A
Oct 13, 2023	fmr llc	-	0	SC 13G/A
Oct 10, 2023	fil ltd	-	0	SC 13G/A
Sep 28, 2023	bioxcel llc	29.2%	8,546,750	SC 13D
Apr 04, 2023	bioxcel holdings, inc.	29.5%	8,546,750	SC 13G/A
Feb 14, 2023	bioxcel holdings, inc.	30.5%	8,546,750	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	0.1%	24,000	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Bioxcel Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	DEFA14A	DEFA14A
Apr 22, 2024	8-K	Current Report
Apr 19, 2024	PRE 14A	PRE 14A
Apr 10, 2024	8-K	Current Report
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading
Apr 08, 2024	4	Insider Trading

Peers (Alternatives to Bioxcel Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	0.98%	-26.98%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-12.72%	-14.31%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	6.98%	-11.75%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	6.22%	110.41%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-16.95%	-51.10%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	9.36%	-4.29%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-10.69%	-43.90%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

Bioxcel Therapeutics Inc News

Latest updates

Bioxcel Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)							(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Revenue	54.8%	582	376	341	457	206	172	137
Costs and Expenses	22.2%	24,745	20,250	48,638	52,871	51,404	53,129	39,127
S&GA Expenses	38.1%	13,264	9,603	24,344	25,872	23,595	20,534	17,054
R&D Expenses	14.8%	11,401	9,934	19,619	26,973	27,800	32,586	22,062
Interest Expenses	5.0%	3,607	3,436	3,252	3,259	3,367	2,920	3,700
Net Income	-20.4%	-26,791	-22,256	-50,486	-53,515	-52,796	-54,808	-41,805
Net Income Margin	32.8%	-87.16*	-129.75*	-187.47*	-231.25*	-298.73*	-442.02*	-
Free Cashflow	34.1%	-17,706	-26,863	-37,584	-38,206	-52,353	-38,639	-31,186

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	11.7%	82.00	74.00	100	140	180	206	245	248	211	239	261	281	200	220	239	70.00	86.00	36.00	44.00	34.00	40.00
Current Assets	12.2%	81.00	72.00	99.00	138	177	203	242	245	208	237	257	277	197	217	236	68.00	84.00	34.00	41.00	32.00	38.00
Cash Equivalents	13.7%	74.00	65.00	90.00	128	166	194	232	233	200	233	253	273	194	213	233	65.00	80.00	32.00	40.00	30.00	36.00
Inventory	22.5%	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-9.9%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	18.8%	155	130	141	134	127	129	118	84.00	17.00	18.00	16.00	14.00	14.00	13.00	18.00	17.00	13.00	9.00	9.00	9.00	8.00
Current Liabilities	15.5%	31.00	27.00	39.00	35.00	29.00	33.00	23.00	20.00	16.00	17.00	15.00	12.00	12.00	12.00	16.00	16.00	12.00	8.00	8.00	8.00	7.00
Long Term Debt	1.0%	102	101	99.00	97.00	95.00	93.00	92.00	61.00	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	101	99.00	97.00	95.00	93.00	92.00	61.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-28.1%	-72.36	-56.51	-	6.00	53.00	77.00	127	164	194	222	246	267	187	207	221	53.00	73.00	27.00	34.00	25.00	32.00
Retained Earnings	-4.5%	-617	-590	-568	-517	-464	-411	-356	-314	-277	-245	-219	-192	-165	-138	-117	-93.02	-71.60	-56.69	-48.41	-39.40	-30.92
Additional Paid-In Capital	2.0%	545	534	528	524	517	488	484	479	471	467	465	460	352	346	339	146	144	84.00	83.00	65.00	63.00
Shares Outstanding	2.2%	31.00	30.00	29.00	29.00	29.00	28.00	28.00	28.00	28.00	28.00	26.00	25.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	135	-	-	-	251	-	-	-	551	-	-	-	565	-	-	-	63.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	34.1%	-17,706	-26,863	-37,584	-38,206	-52,353	-38,639	-31,186	-33,103	-32,413	-19,932	-20,199	-22,382	-19,640	-20,272	-19,101	-14,820	-12,157	-7,919	-7,485	-6,027	-5,670
Share Based Compensation	-4.6%	3,433	3,599	4,014	6,124	4,877	4,547	4,483	4,482	3,825	2,236	4,885	6,769	5,565	6,611	5,268	1,956	776	654	776	1,030	682
Cashflow From Investing	-	-	-	-	-	-	-	-	-19.00	-120	-12.00	-17.00	-100	-316	-270	5.00	-35.00	-16.00	-2.00	-43.00	-225	-600
Cashflow From Financing	1154.2%	26,626	2,123	-	250	24,149	50.00	30,048	-	-	-	71.00	101,524	852	233	187,029	271	59,826	95.00	17,815	-79.00	1.00
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,024	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BTAI Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Product revenue, net	$ 582	$ 206
Operating expenses
Cost of goods sold	80	9
Research and development	11,401	27,800
Selling, general and administrative	13,264	23,595
Total operating expenses	24,745	51,404
Loss from operations	(24,163)	(51,198)
Other expense (income)
Interest expense	3,607	3,367
Interest income	(947)	(2,015)
Other (income) expense, net	(32)	246
Net loss	$ (26,791)	$ (52,796)
Basic net loss per share attributable to common stockholders (in dollars per share)	$ (0.87)	$ (1.84)
Diluted net loss per share attributable to common stockholders (in dollars per share)	$ (0.87)	$ (1.84)
Weighted average shares outstanding - basic (in shares)	30,868	28,616
Weighted average shares outstanding - diluted (in shares)	30,868	28,616

BTAI Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 74,141	$ 65,221
Accounts receivable, net	378	71
Inventory	2,439	1,991
Prepaid expenses	2,103	2,782
Other current assets	1,856	2,078
Total current assets	80,917	72,143
Property and equipment, net	706	784
Operating lease right-of-use assets	613	688
Other assets	87	87
Total assets	82,323	73,702
Current liabilities
Accounts payable	17,220	13,654
Accrued expenses	13,675	12,424
Accrued interest	117	736
Total current liabilities	31,481	27,267
Long-term portion of operating lease liabilities	350	440
Derivative liabilities	21,222	1,905
Long-term debt	101,633	100,598
Total liabilities	154,686	130,210
Commitments and contingencies (Note 16)
Stockholders' (deficit) equity
Preferred stock, $0.001 par value, 10,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, $0.001 par value, 100,000 shares authorized as of March 31, 2024 and December 31, 2023; 33,632 and 29,930 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	34	30
Additional paid-in-capital	544,992	534,060
Accumulated deficit	(617,389)	(590,598)
Total stockholders' (deficit) equity	(72,363)	(56,508)
Total liabilities and stockholders' (deficit) equity	82,323	73,702
Related Party
Current liabilities
Other current liabilities	116	107
Nonrelated Party
Current liabilities
Other current liabilities	$ 353	$ 346

About Bioxcel Therapeutics Inc

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naÃƒÂ¯ve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

CEO	Dr. Vimal D. Mehta Ph.D.
WEBSITE	bioxceltherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	183

Bioxcel Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Bioxcel Therapeutics Inc? What does BTAI stand for in stocks?

BTAI is the stock ticker symbol of Bioxcel Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bioxcel Therapeutics Inc (BTAI)?

As of Mon May 13 2024, market cap of Bioxcel Therapeutics Inc is 81.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BTAI stock?

You can check BTAI's fair value in chart for subscribers.

What is the fair value of BTAI stock?

You can check BTAI's fair value in chart for subscribers. The fair value of Bioxcel Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Bioxcel Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BTAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Bioxcel Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BTAI is over valued or under valued. Whether Bioxcel Therapeutics Inc is cheap or expensive depends on the assumptions which impact Bioxcel Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTAI.

What is Bioxcel Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, BTAI's PE ratio (Price to Earnings) is -0.53 and Price to Sales (PS) ratio is 46.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BTAI PE ratio will change depending on the future growth rate expectations of investors.